138 related articles for article (PubMed ID: 37285145)
1. Risk of Mortality After a Diagnosis of Melanoma In Situ.
Patel VR; Roberson ML; Pignone MP; Adamson AS
JAMA Dermatol; 2023 Jul; 159(7):703-710. PubMed ID: 37285145
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors Associated With First and Second Primary Melanomas in a High-Incidence Population.
Olsen CM; Pandeya N; Dusingize JC; Neale RE; MacGregor S; Law MH; Whiteman DC;
JAMA Dermatol; 2023 Jan; 159(1):37-46. PubMed ID: 36416830
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Incidence Rates Among Non-Hispanic American Indian/Alaska Native Individuals, 1999-2019.
Townsend JS; Melkonian SC; Jim MA; Holman DM; Buffalo M; Julian AK
JAMA Dermatol; 2024 Feb; 160(2):148-155. PubMed ID: 38150212
[TBL] [Abstract][Full Text] [Related]
4. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.
Youlden DR; Youl PH; Soyer HP; Aitken JF; Baade PD
JAMA Dermatol; 2014 May; 150(5):526-34. PubMed ID: 25093216
[TBL] [Abstract][Full Text] [Related]
5. Hospitalization and Mortality Outcomes Among Childhood Cancer Survivors by Race, Ethnicity, and Time Since Diagnosis.
Emerson MA; Olshan AF; Chow EJ; Doody DR; Mueller BA
JAMA Netw Open; 2022 Jun; 5(6):e2219122. PubMed ID: 35763295
[TBL] [Abstract][Full Text] [Related]
6. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
Narod SA; Iqbal J; Giannakeas V; Sopik V; Sun P
JAMA Oncol; 2015 Oct; 1(7):888-96. PubMed ID: 26291673
[TBL] [Abstract][Full Text] [Related]
8. Association Between Melanoma Detected During Routine Skin Checks and Mortality.
Watts CG; McLoughlin K; Goumas C; van Kemenade CH; Aitken JF; Soyer HP; Fernandez Peñas P; Guitera P; Scolyer RA; Morton RL; Menzies SW; Caruana M; Kang YJ; Mann GJ; Chakera AH; Madronio CM; Armstrong BK; Thompson JF; Cust AE
JAMA Dermatol; 2021 Dec; 157(12):1425-1436. PubMed ID: 34730781
[TBL] [Abstract][Full Text] [Related]
9. Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.
Wei EX; Qureshi AA; Han J; Li TY; Cho E; Lin JY; Li WQ
J Am Acad Dermatol; 2016 Oct; 75(4):698-705. PubMed ID: 27436155
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Factors Associated With Second Primary Invasive Melanoma in Norway.
Ghiasvand R; Green AC; Veierød MB; Robsahm TE
JAMA Dermatol; 2024 Apr; 160(4):402-408. PubMed ID: 38416466
[TBL] [Abstract][Full Text] [Related]
11. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas.
Chen T; Fallah M; Försti A; Kharazmi E; Sundquist K; Hemminki K
JAMA Dermatol; 2015 Jun; 151(6):607-15. PubMed ID: 25671687
[TBL] [Abstract][Full Text] [Related]
12. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System.
Matsumoto M; Wack S; Weinstock MA; Geller A; Wang H; Solano FX; Kirkwood JM; Ferris LK
JAMA Dermatol; 2022 May; 158(5):504-512. PubMed ID: 35385051
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of Dermoscopic Criteria for the Diagnosis of Melanoma In Situ.
Lallas A; Longo C; Manfredini M; Benati E; Babino G; Chinazzo C; Apalla Z; Papageorgiou C; Moscarella E; Kyrgidis A; Argenziano G
JAMA Dermatol; 2018 Apr; 154(4):414-419. PubMed ID: 29466542
[TBL] [Abstract][Full Text] [Related]
14. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.
Bradford PT; Goldstein AM; McMaster ML; Tucker MA
Arch Dermatol; 2009 Apr; 145(4):427-34. PubMed ID: 19380664
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Melanoma in Renal Transplant Recipients.
Ascha M; Ascha MS; Tanenbaum J; Bordeaux JS
JAMA Dermatol; 2017 Nov; 153(11):1130-1136. PubMed ID: 28746700
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Clinical Features and Outcomes of Black Patients With Melanoma.
Wix SN; Brown AB; Heberton M; Adamson AS; Gill JG
JAMA Dermatol; 2024 Mar; 160(3):328-333. PubMed ID: 38265787
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
